CLPX

Across TCGA pan-cancer cohorts, CLPX RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CLPX’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CLPX RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLPX is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

BLCA, KIRC, and LUSC are the cancer types where CLPX tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLPX RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.487	<.001	7	view →
KIRC	Male	II,III,IV	−0.461	<.001	6	view →
LUSC	All	All	+0.360	<.001	6	view →
KICH	All	All	−0.610	<.001	4	view →
LUAD	Male	II,III,IV	+0.511	<.001	4	view →
COAD	Male	All	+0.242	.018	3	view →
UCEC	All	All	−0.489	.020	2	view →
KIRP	Male	All	−0.371	.003	2	view →
PRAD	All	All	+0.267	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CLPX–BLCA

Open the BLCA breakdown →